Xuzhou Medical University - The Affiliated Hospital - 3234
Welcome,         Profile    Billing    Logout  
 0 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chen, Bi
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

Recruiting
3
450
RoW
camrelizumab + famitinib, pembrolizumab, camrelizumab
Jiangsu HengRui Medicine Co., Ltd.
Non-small Cell Lung Cancer
12/23
12/25
NCT05243680 / 2020-004334-38: An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)

Active, not recruiting
3
641
Europe, Canada, Japan, US, RoW
GSK3511294 (Depemokimab)
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
05/25
05/25
PRESERVE-003, NCT05671510: ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

Active, not recruiting
3
600
Europe, Canada, US, RoW
Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere
OncoC4, Inc., BioNTech SE
Non Small Cell Lung Cancer
06/26
06/27
NCT05292196: A Phase II Clinical Trial of TQC3721 Suspension for Inhalation

Recruiting
2
460
RoW
TQC3721 suspension for inhalation, TQC3721 suspension placebo for inhalation
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Obstructive Pulmonary Disease (COPD)
01/24
05/24
HLX26HLX10-NSCLC201, NCT05787613: A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients

Recruiting
2
132
RoW
HLX26, Anti-LAG-3 monoclonal Antibody Injection, Serplulimab, HLX10, Chemotherapy drug, Placebo
Shanghai Henlius Biotech
NSCLC Stage IV
07/25
07/27
NCT05767866: Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR

Recruiting
1/2
160
RoW
YK-029A
Suzhou Puhe Pharmaceutical Technology Co., LTD
Treatment, Treatment Side Effects
12/23
05/24
NCT05360381: HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors

Active, not recruiting
1
82
RoW
HLX35
Shanghai Henlius Biotech
Locally Advanced or Metastatic Solid Tumors, Squamous-cell Non-small Cell Lung Cancer
10/24
12/24
Zhang, Jiliang
PRESERVE-003, NCT05671510: ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

Active, not recruiting
3
600
Europe, Canada, US, RoW
Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere
OncoC4, Inc., BioNTech SE
Non Small Cell Lung Cancer
06/26
06/27

Download Options